Media coverage about Pediapharm (NASDAQ:PDP) has been trending somewhat positive this week, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Pediapharm earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.9797564226512 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of Pediapharm (NASDAQ:PDP) opened at $52.55 on Friday. The stock has a market capitalization of $1,560.00, a P/E ratio of 11.18 and a beta of 0.95. Pediapharm has a 52 week low of $42.16 and a 52 week high of $52.68.
In related news, Director Benoit Gravel acquired 146,000 shares of the company’s stock in a transaction dated Tuesday, October 17th. The stock was purchased at an average price of $0.30 per share, with a total value of $43,800.00.
WARNING: This piece of content was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3126401/pediapharm-pdp-receiving-somewhat-positive-news-coverage-analysis-shows.html.
PowerShares DWA Technical Leaders Portfolio (the Fund) is based on the Dorsey Wright Technical Leaders Index (the Index). The Fund seeks investment results that generally correspond to the price and yield of the Index. The Fund will normally invest at least 90% of its total assets in securities that consists of the Index and American Depositary Receipts (ADRs) based on the securities in the Index.
Receive News & Ratings for Pediapharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediapharm and related companies with MarketBeat.com's FREE daily email newsletter.